{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-044817","form_type":"8-K","ticker":"STIM","cik":"0001227636","company_name":"Neuronetics, Inc.","filed_at":"2025-03-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.130069+00:00","generated_at":"2026-05-25T12:59:58.434156+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Neuronetics Q4 rev $22.5M (+11% YoY); closes Greenbrook TMS, guides FY25 rev $145-155M","bullets":["Q4 2024 total revenue $22.5M (+11% YoY); U.S. treatment session revenue $12.9M; clinic revenue from Greenbrook $4.4M.","Net loss Q4 $(12.2)M or $(0.33) per share vs $(5.4)M or $(0.19) in Q4 2023.","Acquired Greenbrook TMS on Dec 9, 2024 adding 95 U.S. clinics; secured $10M from Perceptive Advisors at close.","Realized over $21M of $22M targeted annualized cost synergies from Greenbrook integration.","Completed $18.9M secondary offering in Feb 2025; guides FY25 rev $145-155M and Q3 2025 cash flow positive."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-044817","json":"https://secwatch.observer/filing/0001193125-25-044817.json","markdown":"https://secwatch.observer/filing/0001193125-25-044817.md","text":"https://secwatch.observer/filing/0001193125-25-044817.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1227636/000119312525044817/0001193125-25-044817-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1227636/000119312525044817/d894924d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T12:59:58.434156+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}